INTRODUCTION
Islet activating protein is one ofthe pertussis toxins that can be isolated and purified to homogeneity from the culture medium of the whooping cough bacterium, Bordatellapertussis (Yajima et al., 1978) . This toxin is so named because it was noticed first to cause a sustained potentiation of the secretory response of pancreatic islet cells to a variety of stimuli (see, e.g., Katada & Ui, 1980) . More recently it has become of interest due to its ability to block the receptor-mediated inhibition of adenylate cyclase in various cells (see, e.g., Katada & Ui, 1981; Hazeki & Ui, 1981; Kurose et al., 1983) including hepatocytes (Heyworth et al., 1984b) as well as to potentiate the stimulation of adenylate cyclase by fl-adrenergic agents in C6-glioma cells (Katada et al., 1982) and by glucagon in hepatocytes (Heyworth et al., 1984b) .
Islet activating protein appears to exert these effects upon adenylatecyclasebytriggeringtheADP-ribosylation of a specific guanine nucleotide regulatory protein, called Ni (see, e.g., Bokoch et al., 1983; Codina et al., 1983; Hanski & Gilman, 1982; Heyworth et al., 1984b; Katada et al., 1982) . N1 has been demonstrated to mediate the action ofinhibitory receptors upon adenylate cyclase (see, e.g., Hildebrandt et al., 1982 Hildebrandt et al., , 1983 Jakobs & Schultz, 1983) and has recently been purified to apparent homogeneity (Bokoch et al., 1983; Hanski & Gilman, 1982) . It is a distinct species from the guanine nucleotide regulatory protein, N8, which mediates the action of stimulatory hormone receptors upon adenylate cyclase (see, e.g., Gilman, 1984; Houslay, 1984) . However, N8, Ni and transducin, a guanine nucleotide regulatory protein that mediates the rhodopsin-catalysed activation of a cyclic GMP phosphodiesterase in retinal rods, all exhibit a similar trimeric structure: distinct a. subunits, apparently identical , subunits and very similar y subunits (Manning & Gilman, 1983; Gilman, 1984) . This common basic structure is believed to play an inherent part in their activation mechanism which, in each case, appears to result as a consequence of their dissociation to release an a subunit from the complex. In the case of Ns and transducin it is the activated a subunit which now exerts a stimulatory effect on the adenylate cyclase and the cyclic GMP phosphodiesterase respectively. With Ni, however, it is considered that the fl-y complex released upon activation of Ni actually inhibits Ns dissociation by mass action and yields an inhibitory response (Gilman, 1984) .
We have suggested that insulin might exert certain of its effects through interactions with the guanine nucleotide regulatory protein system in plasma membranes (see . This was suggested to account for the ability of insulin to (i) activate a plasma membrane cyclic AMP phosphodiesterase, in broken membranes and intact cells , and (ii) inhibit adenylate cyclase in a GTP-dependent manner . It has been proposed by us that a specific species of guanine nucleotide regulatory protein, called Nin., might mediate the action of insulin in stimulating the peripheral plasma membrane cyclic AMP phosphodi-esterase. This regulatory protein has been tentatively identified as an Mr-25 000 species (Heyworth et al., 1985a) .
Here we examine the effects of islet activating protein upon the ability of insulin to activate both the peripheral plasma membrane and' dense-vesicle' phosphodiesterases in intact hepatocytes and to inhibit adenylate cyclase both in intact hepatocytes and in a broken membrane system. In these studies we have chosen to pretreat the intact hepatocytes with islet activating protein rather than the whole animals. This is because treatment of animals with islet activating protein leads to an increase in insulin secretion (Katada & Ui, 1979) which might be expected to perturb insulin responsive processes perhaps by initiating some refractoriness in the hormonal response.
MATERIALS AND METHODS
Hepatocytes were prepared from fed, 200-300 g male Sprague-Dawley rats by the method of Elliott et al. (1976) . They were then preincubated at 37°C in Krebs-Henseleit (1932) buffer containing 2.5% bovine serum albumin and 2.5 mM-CaCl, for 20-30 min prior to their use. All subsequent incubations were performed at the same temperature with the same buffer, i.e. under conditions described by us previously in some detail . For the longer incubations employed with pertussis toxin then 10 mM-glucose was added to the incubation medium and cells were re-gassed every 15 min for 1 min with 02/CO2 (19:1). Intracellular cyclic AMP was determined as described in detail previously (Whetton et al., 1983 ) using centrifugation of the cells through bromododecane into HClO4/sucrose and determination ofcyclic AMP in a neutralized sample by using the heart muscle binding protein assay of Rubin et al. (1975) . ATP concentrations were ascertained by using the firefly luciferase assay as described before . Assessment of activation of the plasma membrane and 'dense-vesicle' cyclic AMP phosphodiesterase activity by insulin was made as before by using the rapid Percoll fractionation procedure to separate out the various subcellular components of the hepatocytes. As detailed previously it was crucial to ensure a good separation of the plasma membranes from the endoplasmic reticulum fractions, otherwise the significant cyclic AMP phosphodiesterase activity in the endoplasmic reticulum fraction obscured the insulin-mediated activation of the plasma membrane enzyme. Adequate separation of these fractions was ensured by 'calibrating' each batch of Percoll to give marker enzyme separation profiles as detailed previously . Such 'calibration involved the fine adjustment of the speed of centrifugation in order to obtain the required separation profile, as detailed in .
The effects of insulin action on the adenylate cyclase activity of a plasma membrane fraction prepared from hepatocytes (Houslay & Elliott, 1979 was performed as detailed previously by us . Briefly, adenylate cyclase was assayed in 0.1 ml final volume. The mixture had final concentration of 0.1 mM-GTP, 0.1 nM-glucagon, 5 mM-MgSO4, 10 mM-theophylline, 1 mM-EDTA, 22 mM-disodium phosphocreatine, 1.5 mM-ATP, 1 mM-dithiothreitol, 1 mg of creatine kinase/ml, 25 mM-triethanolanine/HCl neutralized to a final pH 7.4 with KOH, and 0.1 mg ofmembrane protein. It was essential to use the highly purified phosphocreatine from Boehringer (Lewes, East Sussex, U.K.) rather than other sources, to add GTP to the assays and to employ low concentrations ofglucagon in order to observe such inhibitory actions ofinsulin on adenylate cyclase. All solutions were made up fresh every 2-3 days. Incubations were carried out over 10 min at 30°C during which time assays were linear. After immersion in boiling water for 3 min, to stop the reaction, cyclic AMP produced in the assay was determined by using a purified cyclic AMP binding protein procedure as detailed above Whetton et at., 1983) . Such an assay method obviates any requirement for a 'sink' of (unlabelled) cyclic AMP in the assay (see, e.g., Salomon et al., 1974) which may inhibit insulin's effects, as elevated cyclic AMP concentrations have been shown to inhibit certain of insulin's actions, e.g. stimulation ofglucose transport (see Houslay, 1985, for review) . Similar results could be obtained with a liver plasma membrane preparation obtained as described previously by us .
Cyclic AMP phosphodiesterase activity was determined at a final substrate concentration of 10-7 M-cyclic AMP as detailed before . Samples derived from the Percoll gradients were treated as described by prior to assay. Initial rates were taken from linear time courses.
All materials were as specified in the publications cited in this section. All radiochemicals were from Amersham International, Amersham, Bucks., U.K., except for [32P]NAD+, which was from New England Nuclear. 
RESULTS
We have previously demonstrated ) that insulin can inhibit the adenylate cyclase activity of hepatocyte plasma membranes provided that only low, physiological glucagon concentrations (approx. 0.1 nM) were present together with GTP (0.1 mM) in the assays. However, if plasma membranes were prepared from hepatocytes treated with islet activating protein, then insulin (1.0 nM) failed to inhibit the activity of glucagon (+ GTP)-stimulated adenylate cyclase (Table 1 ). In contrast, insulin still inhibited adenylate cyclase activity in membranes prepared from hepatocytes incubated similarly, but without islet activating protein (Table 1) .
When intact hepatocytes were incubated with 3-isobutyl-1-methylxanthine (1 mM), to inhibit cyclic AMP phosphodiesterase activity then, in the presence of low concentrations of glucagon (0.1 nM), insulin (10 nM) inhibited the rate of formation of cyclic AMP by adenylate cyclase. However, when the hepatocytes were pretreated with islet activating protein (100 ng/ml), for 1 h, this inhibitory effect of insulin on the adenylate cyclase activity ofwhole cells was abolished (Fig. 1) .
Insulin (10 nM) treatment of intact hepatocytes leads to the activation of at least two specific cyclic AMP phosphodiesterases, the peripheral plasma membrane Table 1 . Pertussis toxin blocks the inhibitory action of insulin upon adenylate cyclase activity in rat liver plasma membranes Hepatocytes were incubated for 1 h either with or without islet activating protein/pertussis toxin (100 ng/ml) prior to the preparation of a membrane fraction for adenylate cyclase assay. Inhibition of glucagon-stimulated adenylate cyclase by insulin (1.0 nM) was seen provided that physiological, low glucagon concentration (0.1 nm) are employed together with GTP (0.1 mM) (see Fig. 1 . Pertussis toxin blocks insulin's inhibition of adenylate cyclase activity in intact hepatocytes Hepatocytes were incubated as described previously by us and then, at the designated time interval, harvested for determination of intracellular cyclic AMP concentration (Whetton et al., 1983) . In this instance cells were preincubated for 10 min with 3-isobutyl-lmethylxanthine (1 mM) in order to inhibit cellular cyclic enzyme and the 'dense-vesicle' enzyme Wilson et al., 1983) . The degree of activation of each species can be assessed after the resolution of cyclic AMP phosphodiesterase activity associated with various subcellular fractions upon Percoll gradient fractionation ofhepatocyte homogenates. Here we observed (errors are S.E.M., for n = 3 separate experiments) that insulin's activation of the ' dense-vesicle' phosphodiesterase was in fact markedly reduced from 140% ±4% in control cells to 115% ± 5% (significant activation at P = 0.05) in cells pre-treated for 1 h with islet activating protein (100 ng/ml). Table 2 shows that the ability of insulin to activate the plasma membrane cyclic AMP phosphodiesterase was unaffected by prior exposure of the hepatocytes to islet activating protein (100 ng/ml for 1 h). However, we see here that the treatment of hepatocytes with islet activating protein actually prevented glucagon from blocking insulin's activation of the plasma membrane cyclic AMP phosphodiesterase (Table 2) . We noted that treatment with glucagon alone did not activate this enzyme in hepatocytes that had been pretreated with islet activating protein (100 ng/ml for 1 h).
The effect of islet activating protein on inhibitory responses connected with adenylate cyclase is dependent upon the concentration of islet activating protein used, the time and temperature of exposure and the particular cell type under investigation (see, e.g., Hazeki & Ui, 1981; Katada et al., 1982; Murayama et al., 1983) . We believe that, under the conditions employed here, maximal effects of islet activating protein were observed. This is because we noted little significant differences in the effects reported here by incubating either with islet activating protein at 1 jug/ml instead of 100 ng/ml for 1 h or by incubating for up to 2 h with 100 ng of islet activating AMP phosphodiesterase activity. Additions of either glucagon (0.1 nM) alone (M) or both glucagon (0.1 nM) and insulin (10 nM) together (A) were made. In (a) control cells were used which had been incubated for 1 h prior to exposure to the ligands, whereas in (b) the cells had been preincubated for 1 h with islet activating protein (100 ng/ml). The Hepatocytes were incubated, as described previously by us , for 1 h either without or with islet activating protein (100 ng/ml) as described in the Materials and methods section. Additions of hormones were then made to the hepatocyte incubations as shown in the Table. The total incubation time, with the ligands, is shown in parentheses. Cells were then harvested, by centrifugation, and the degree of activation of the peripheral plasma membrane cyclic AMP phosphodiesterase assessed from a Percoll gradient fractionation as detailed before by us (10 nM) (5 min) protein/ml. In this respect hepatocytes respond somewhat faster to islet activating protein compared with other cell types, as has been shown to be the case for the action of cholera toxin on these cells (Houslay & Elliott, 1979 .
DISCUSSION
We (Heyworth et al., 1984b) and others (Itoh et al., 1984) (Heyworth et al., 1985a ).
Here we see that exposure of hepatocytes to islet activating protein obliterates the inhibitory effect of insulin on adenylate cyclase (Table 1 ; Fig. 1 ). This inhibitory action of insulin has been shown previously by us to be dependent upon the presence of Na+ in the assay mixture and to be abolished by replacing Mg2+ with Mn2+ in the assay mixture . Such evidence suggests that insulin exerts its inhibitory effect on adenylate cyclase through the inhibitory guanine nucleotide regulatory protein, Ni.
Prior exposure of hepatocytes to glucagon, before insulin, initiates the development of a selective 'insulinresistant' state. This manifests itself as an inability of insulin to both inhibit adenylate cyclase and to activate the peripheral plasma membrane cyclic AMP phosphodiesterase in such glucagon pretreated cells Heyworth et al., , 1985b Wallace et al., 1984) . This action of glucagon appears to be cyclic AMP-independent and its characteristics are remarkably similar to those of the process whereby glucagon elicits the desensitization of adenylate cyclase in intact hepatocytes (Heyworth&Houslay, 1983a) . We (Heyworth et al., 1984b) and others (Rich et al., 1984) Here we see ( Table 2 ) that in hepatocytes, which have been pretreated with islet activating protein, insulin can still activate the peripheral plasma membrane cyclic AMP phosphodiesterase. This adds support to our contention (Heyworth et al., 1983a, b ) that insulin does not activate this enzyme by a process involving Ni. However, we also show here that the ability of glucagon pretreatment of hepatocytes to block insulin's activation of this enzyme is abolished in cells treated with islet activating protein ( Table 2) . Thus islet activating protein is like the phorbol ester 12-0-tetradecanoylphorbol 13-acetate (TPA) (Heyworth et al., 1985b) and adenosine (Wallace et al., 1984) in both eliciting this action and also in blocking glucagon-desensitization of adenylate cyclase. One common factor that might link these observations is an action at the level of Ni.
Intriguingly the activation of the 'dense-vesicle' enzyme was inhibited in pertussis toxin-pretreated hepatocytes. This confirms studies (Elks et al., 1983) performed on the equivalent enzyme found in adipocytes and supports our contention (Wilson et al., 1983 ) that the plasma membrane and 'dense-vesicle' phosphodiesterase are activated by insulin through distinct routes. Whether activation of the 'dense-vesicle' enzyme involves a guanine nucleotide regulatory protein, such as either Ni or No (GI/Go), which are both pertussis toxin substrates (Sternweiss & Robishaw, 1984) , remains to be seen. Our earlier evidence (Wilson et al., 1983) suggested that the 'membrane processing' of either the internalized insulin receptor or a vesicle fraction containing the 'dense-vesicle' phosphodiesterase, was involved in eliciting the activation of the 'dense-vesicle' enzyme. It is possible, as pertussis toxin affects membrane-mediate secretory responses (see, e.g., Katada & Ui, 1979 , 1980 Nakamura & Ui, 1985) , that 'membrane traffic' phenomena within the cell are affected by this toxin.
We have accrued considerable evidence which, up until the present study, suggested that insulin might exert its actions on both adenylate cyclase and on the peripheral cyclic AMP phosphodiesterase through a similar mechanism involving a distinct guanine nucleotide regulatory protein called Nin, (see Houslay & Heyworth, 1983; Houslay, 1985) . Our observations which show here that pertussis toxin can discriminate between these two insulin-mediated processes clearly casts doubt on such a hypothesis. However, whereas pertussis toxin clearly obliterates the inhibitory effect of insulin on adenylate cyclase (Table 1) we should take note that cholera toxin also achieves a similar result . As pertussis toxin can exert actions other than just through N1 (Sternweiss & Robishaw, 1984) it might still be prudent to keep in mind that insulin could inhibit adenylate cyclase through the putative Nin,, with pertussis toxin eliciting its action through an indirect means. One possible mechanism is discussed elsewhere (Houslay, 1986) .
We would like to suggest that these results add further support to our contention (see ) that the insulin receptor can interact with the guanine nucleotide regulatory protein system in liver plasma membranes.
